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Abstract
Background: Our aim was to study the effects of visual feedback cues, responding dynamically to patient’s self-motion and provided through a portable see-
through virtual reality apparatus, on the walking abilities of patients with Parkinson’s disease.
Methods: Twenty patients participated. On-line and residual effects on walking speed and stride length were measured.
Results: Attaching the visual feedback device to the patient with the display turned off showed a negligible effect of about 2%. With the display turned on, 56% of
the patients improved either their walking speed, or their stride length, or both, by over 20%. After device removal, and waiting for 15 minutes, the patients were
instructed to walk again: 68% of the patients showed over 20% improvement in either walking speed or stride length or both. One week after participating in the
first test, 36% of the patients showed over 20% improvement in baseline performance with respect to the previous test. Some of the patients reported that they still
walked on the tiles in their minds.
Discussion: Improvements in walking abilities were measured in patients with Parkinson’s disease using virtual reality visual feedback cues. Residual effects suggest
the examination of this approach in a comprehensive therapy program.
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Introduction
People with Parkinson’s disease (PD) typically show a combination of
rest tremor, rigidity, hypokinesia, and postural instability. As the disease
progresses, gait is affected, resulting in decreased stride length and
walking speed. Levodopa and dopamine agonists, particularly effective
in early stages of the disease, lose efficacy with disease progression.
Recent functional neurosurgery studies demonstrate beneficial effects of
pallidotomy and subthalamic nucleus (STN) stimulation on motor
symptoms in PD.1,2 Studies on the effects of STN stimulation on gait
have shown improvement ranging from 36% to 68% on the Unified
Parkinson’s Disease Rating Scale gait sub-score scale.3–5 A common
non-pharmacological approach to treating gait difficulties in PD is
physical therapy. This used to be the principal treatment modality prior
to the levodopa era and was renewed when the responsiveness to
medications was found to decrease with time.6–8 However, due to
conflicting results concerning the efficacy of physical therapy,9,10 there is
not yet consensus as to whether it should be routinely prescribed within a
rehabilitation program for patients with PD.9–12
Neurophysiological studies have suggested that internal cue
production is defective in PD patients.13–15 On the other hand,
several studies have demonstrated that external stimuli, such as
auditory, visual, and cutaneous cues, enhance gait performance in such
patients.16–21 It has been hypothesized that external sensory cues help
patients with PD switch from one movement component of a sequence
to the next, bypassing the defective internal trigger from the pallidum
to the supplementary motor area.22,23
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Early devices for providing external stimuli employed open-loop
strategies that imposed a sensory signal on the patient, generated by an
external source, which is not affected by the patient’s own motion,
such as fixed-velocity (treadmill-like) visual cues.24,25 A study of the
closed-loop effects of real-world visual cues on the regulation and
stabilization of gait26 has led to the development of a portable feedback
control augmented reality apparatus that displays a virtual tiled floor
responding dynamically to the patient’s self-movement. In a previous
preliminary study on patients with PD taken off their medications27 we
found that the closed-loop device improved gait in these patients
beyond the effects of the open-loop version, which was found to cause
frustration, and even freezing of gait, in some of the patients. Gait
improvement was also found in patients with multiple sclerosis using
the same device.28 The purpose of the present study was to investigate
the on-line and residual effects of the closed-loop apparatus on patients
with PD on their regular medication schedule.
Methods
Subjects
Twenty-seven patients were recruited, but only 20 patients
completed the study; 15 men and five women, average age 71.25
years, mean disease duration 5.28 years, and Hoehn–Yahr29 range
2.5–4 participated in the study. Participants were on their regular anti-
parkinsonian medication. Patients with considerable visual deficit not
compensated by correction, ocular movement dysfunction, and gait
disturbances due to neuromuscular diseases were excluded. Disease-
related disability was assessed using the Hoehn and Yahr scale. All
patients provided signed informed consent, and the local Ethics
Committee approved the study according to the Helsinki agreement.
Assessment of ambulation
Assessment of patient ambulation was based on walking speed (m/
second) and stride length (m), calculated directly from measurements
of time and number of steps needed to complete a fixed straight track
of 10 m.
Virtual reality apparatus
Visual cues were generated by a belt-mounted unit, housing motion
sensors and digital processing components, and delivered by a micro-
display (Figure 1). The display, attached to the eyeglasses frame,
provides the patient with a virtual tiled floor in a checkerboard
arrangement, responding dynamically to the patient’s own motion,
meaning that the patient has the ability to dynamically change walking
skills and quality in response to external cues; much like walking on a
real floor, fixed in space. The small size of the display and the see-
through feature of its enclosure ensure that the field of view is
effectively unobstructed.
Procedure
All tests were performed at the Carmel Medical Center, Haifa,
Israel, between September 2010 and December 2011 at about the
same time in the afternoon. Examination comprised five stages, each
consisting of the patient walking a straight track of 10 m: baseline,
online display off, online display on, residual effects, and examination.
At each stage, the length of time to complete the 10-m track and the
number of steps were recorded four times and averaged. At the start of
each stage, the patient was instructed to ‘‘walk normally’’, so as to
reduce motivational factor.
Stage 1: Walking without the device for measurements of baseline
performance.
Stage 2: Walking with the device placed on the patient, but with the
display turned off, in order to measure the pre-conditioning effect.
Stage 3: Walking with the display turned on in order to produce and
measure the on-line effect of the virtual tiled floor. Patients were
instructed to ‘‘walk on the virtual tiles’’, using their imagination in
trying to ‘‘reach for the next tile’’ with each of their feet. No further
restrictions, regarding stepping on tiles of specific color or not stepping
on tile edges were imposed or suggested.
Stage 4: Walking without the device after a 15-minute break, in
order to measure the short-term residual effect of the visual feedback
cues.
Stage 5: Re-evaluation of baseline performance without the device 1
week after the first examination, in order to measure the long-term
residual effect of the visual feedback cues.
Wilcoxon’s signed rank test was used to compare between speed and
stride length at each stage compared to baseline speed and stride
length levels, respectively. Also Pearson correlation tests were used to
correlate between the Hoehn–Yahr scale and both speed and stride
length separately.
Results
The clinical test results are given in Table 1.
With the device mounted on, but the display turned off, the patients
showed 1.75% (p50.126) improvement in walking speed and 2.61%
improvement (p50.073) in stride length, on average, with respect to
the baseline performance. These changes represent a negligible
Figure 1. Visual-feedback Virtual Reality Device Used in Tests.
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‘‘placebo’’ effect. Turning the display on, there was a significant
improvement in both walking speed (p50.002) and stride length
(p50.002) compared to baseline, where 65% of the patients improved
either their walking speed or their stride length or both by over 10%,
and 55% of the patients showed over 20% improvement. Following
the 15-minute break, there was still a significant improvement in
walking speed (p50.000) and stride length (p50.000), compared to
baseline, where 85% of the patients showed over 10% improvement
Table 1. Test Results for Patients with PD: Walking Speed (m/second), and Stride Length (m)
Patient Baseline Display Off Display On 15-min Residual








1 80 M 10 3.5 0.782 0.500 0.752 0.488 0.790 0.677 0.867 0.533
2 75 F 3 2.5 0.669 0.408 0.628 0.400 0.627 0.400 0.747 0.435
3 77 M 3 3 0.848 0.476 0.816 0.465 0.954 0.541 1.059 0.588
4 61 M 1 3 1.066 0.526 1.071 0.526 1.310 0.625 1.147 0.571
5 79 F 19 3.5 0.680 0.408 0.686 0.400 0.618 0.444 0.735 0.426
6 83 M 5 2.5 0.675 0.426 0.746 0.444 0.606 0.454 0.815 0.454
7 67 M 10 3 1.229 0.645 1.368 0.694 1.426 0.769 1.530 0.741
8 60 M 1 3 1.100 0.606 0.980 0.555 1.373 0.769 1.238 0.667
9 53 F 3 3 1.074 0.625 1.161 0.645 1.100 0.588 1.314 0.645
10 62 M 5 3 1.291 0.645 1.316 0.667 1.356 0.667 1.517 0.741
11 68 M 9 3 0.980 0.513 1.021 0.526 1.358 0.714 1.285 0.588
12 80 M 4 2.5 0.829 0.500 0.933 0.526 1.151 0.588 1.033 0.571
13 78 F 5 2.5 0.602 0.417 0.694 0.435 0.752 0.454 0.849 0.500
14 77 M 5 2.5 0.818 0.513 0.946 0.556 1.063 0.645 1.104 0.588
15 73 M 1 3 0.539 0.308 0.591 0.339 0.808 0.476 0.873 0.500
16 70 M 3.5 3.5 0.370 0.200 0.232 0.150 0.380 0.208 0.375 0.227
17 61 F 7 2.5 0.422 0.323 0.460 0.333 0.439 0.333 0.440 0.345
18 74 M 5 3 0.154 0.376 0.133 0.427 0.294 0.343 0.282 0.374
19 72 M 5 3.5 0.027 0.028 0.022 0.026 0.020 0.025 0.033 0.030
20 75 M 1 4 0.389 0.263 0.486 0.357 0.525 0.408 0.479 0.357
Mean 71.251 5.27 3.0 0.727 0.435 0.752 0.448 0.847 0.506 0.886 0.494
p
Value
0.1262 0.0733 0.0022 0.0023 0.0002 0.0003
DD: Disease Duration (years); H–Y: Hoehn–Yahr Staging; PD: Parkinson’s Disease.
‘‘Display off’’ columns present walking speed and stride length results for patients wearing the device with the display turned off. ‘‘Display on’’ columns show on-line
performance results with the display turned on. ‘‘15-min Residual’’ columns present performance results after a 15-minute break, when patients walked freely with the
device taken off.
1Mean age.
2Compared to baseline speed.
3Compared to baseline stride length.
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and 65% showed over 20% improvement in either walking speed or
stride length or both, without the device. The differences between
residual and on-line performance can be attributed to burdening and
learning effects associated with using the device for the first time, and
are expected to diminish with further training. There was no
significant correlation between Hoehn–Yahr scale at enrollment and
either walking speed change (p50.446) or stride length change
(p50.685) at the different stages.
One week after participating in the first test (where the patient used
the device for approximately 20 minutes), 11 of the patients returned
for another ‘‘baseline’’ test. Of these patients, 64% showed over 10%
improvement and 36% showed over 20% improvement in their
baseline performance. Two of the patients reported that, a week later,
they still walked on the virtual tiles in their minds.
Discussion
In this study we found that the on-line visual feedback-induced
improvement in the walking abilities of patients on their regular
medication schedule (56% of the patients showing over 20%
improvement in either walking speed or stride length) is similar to
that found in our previous study27 on patients taken off their
medication for 12 hours (57% of the patients improving by over
20%). Furthermore, the present study shows that, following virtual
reality (VR) training, PD patients experience a sustained improvement
in their walking abilities. This finding is in line with a recent case study,
showing a sustained improvement in a single subject following 1-
month training with visual cues placed on the ground.30
Patients’ medications were unchanged during the study and subjects
were individually examined with the VR device for walking
performance on a unified planned time-table. Stages 1–4 of the
measurements were taken in one clinical visit, and whole improvement
results were related to the baseline, which was also carried out with the
medication unchanged during the same visit. The last stage of
measurement was 1 week after, without changes in medications. So the
entire improvement was most probably attributed to the device.
The fact that PD patients on a regular medication schedule, trained
with a visual feedback VR device for less than 20 minutes, have a
persistent significant improvement in both stride length and walking
speed with only a slight decline is particularly encouraging. Some
patients described it as a sensation of walking on the tiles in their mind.
This interesting ‘‘learning process’’ can be supported by animal model
studies suggesting that basal ganglia provide an internal non-specific
cue to trigger movements and imply that PD involves a deficiency in
this cueing.13 However, PD patients typically rely upon external visual
cues.16 It is possible that such external cues perpetuate imprinting of
an internal cue, forming a ‘‘cue memory’’ that helps to maintain
certain motor skills.
Using the VR device, walking on a flat surface aims to provide the
patients with a simple training tool to improve motor skills, first by
walking on ground, as evaluated in this study. However, similar
training on a larger scale might also have an effect on postural stability
and on more complex walking tasks, such as performing accurate
strides before and during turning or avoiding stumbling on obstacles.
The effect of VR training on freezing of gait in PD should also be
interesting to look at, mainly because freezing responds poorly to
medication. These aspects should be investigated further.
Since PD is a chronic progressive disease, we suggest that the visual
feedback VR technique should be examined as a long-term procedure
in addition to physical therapy to maintain gait and postural
performances in PD patients.
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